Greenwich LifeSciences Expands Breast Cancer Immunotherapy Trial to Italy
• Greenwich LifeSciences partners with Gruppo Italiano Mammella (GIM) to expand its Phase III FLAMINGO-01 trial in Italy.
• Nine top Italian institutions will participate in evaluating GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence.
• In 2022, Italy reported 58,160 new breast cancer cases, highlighting the critical need for improved treatments and preventative strategies.
• Patient enrollment has commenced at Italian sites, with Professor Grazia Arpino leading as the Italian National Principal Investigator.
Secure Multiparty Computation Enables Privacy-Friendly Evaluation of Patient Data in Adrenal Gland Metastasis Study
• A bicenter, prospective, longitudinal observational study utilized MR-guided radiotherapy (MRgRT) to treat adrenal gland metastasis, emphasizing precision and minimizing radiation exposure.
• Secure multiparty computation (MPC) was employed to analyze patient data jointly between two sites while maintaining data privacy and adhering to strict data protection laws.
• The MPC framework, including Sharemind MPC and Federated Secure Computing, ensured that data remained within each clinical site, with only aggregate results accessible to researchers.
• This approach facilitated detailed studies on rare cancers like adrenal gland metastases, overcoming privacy obstacles and advancing personalized oncology through collaborative data analysis.
Real-world Outcomes of Advanced Renal Cell Carcinoma Treatment with Immune-oncology Combinations
A retrospective study involving 930 patients from 58 centers across 20 countries evaluated the effectiveness of immune-oncology combinations in treating advanced renal cell carcinoma (RCC). The study found that intermediate-risk patients benefited more from a combination of immunotherapy and antiangiogenic therapy (IO + TKI) compared to double immunotherapy (IO + IO), showing longer progression-free survival (PFS) and overall survival (OS). However, no significant difference was observed in poor-risk patients between the two treatment strategies.
© Copyright 2025. All Rights Reserved by MedPath